Nikki

Birth Control, Acne Vulgaris, Folate supplementation therapy + 9 more

Treatment

20 Active Studies for Nikki

What is Nikki

Drospirenone

The Generic name of this drug

Treatment Summary

Drospirenone is a synthetic hormone found in some birth control pills, such as Yaz. It is also used to treat hormonal issues, such as acne and PMDD. While there have been some concerns about an increased risk of blood clots with drospirenone, the FDA has concluded that this risk is still lower than the risk during pregnancy and postpartum.

Yasmin

is the brand name

image of different drug pills on a surface

Nikki Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Yasmin

Drospirenone

2001

64

Effectiveness

How Nikki Affects Patients

Drospirenone is a contraceptive drug that stops ovulation, preventing pregnancy. It also helps to reduce acne and hirsutism. When taken with ethinyl estradiol, it can also help improve certain blood fats. In comparison to other progesterone contraceptives, drospirenone is thought to cause fewer side effects such as breast tenderness and mood swings. However, drospirenone use is associated with an increased risk of blood clots, especially for smokers and women over 35. Additionally, drospirenone may cause a condition called hyperkalemia, which can be dangerous. People at high risk for hyper

How Nikki works in the body

Drospirenone and ethinyl estradiol work together to prevent pregnancy. They stop the body from releasing hormones that cause ovulation and make changes to the cervical mucus that keep sperm from reaching the egg. Drospirenone is similar to a diuretic, so it makes the body get rid of more sodium and water. It also blocks the effects of androgens, which are hormones that can cause acne and unwanted hair growth. Finally, drospirenone may reduce the amount of swelling in the sebaceous follicles that causes acne during the second half of the menstrual cycle.

When to interrupt dosage

The amount of Nikki is contingent upon the diagnosed affliction, such as moderate to severe symptoms, Menopause and Post-Menarche. The measure of dosage fluctuates in connection to the mode of delivery (e.g. Tablet, film coated - Oral or Oral) shown in the table underneath.

Condition

Dosage

Administration

Birth Control

, 0.25 mg, 0.5 mg, 3.0 mg, 1.0 mg, 4.0 mg

, Kit, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral

moderate to severe symptoms

, 0.25 mg, 0.5 mg, 3.0 mg, 1.0 mg, 4.0 mg

, Kit, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral

N-Cadherins

, 0.25 mg, 0.5 mg, 3.0 mg, 1.0 mg, 4.0 mg

, Kit, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral

Hormonal Contraception

, 0.25 mg, 0.5 mg, 3.0 mg, 1.0 mg, 4.0 mg

, Kit, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral

Vasomotor System

, 0.25 mg, 0.5 mg, 3.0 mg, 1.0 mg, 4.0 mg

, Kit, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral

Acne Vulgaris

, 0.25 mg, 0.5 mg, 3.0 mg, 1.0 mg, 4.0 mg

, Kit, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral

Adherence to Oral Contraceptive Therapy

, 0.25 mg, 0.5 mg, 3.0 mg, 1.0 mg, 4.0 mg

, Kit, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral

Atrophic

, 0.25 mg, 0.5 mg, 3.0 mg, 1.0 mg, 4.0 mg

, Kit, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral

Post-Menarche

, 0.25 mg, 0.5 mg, 3.0 mg, 1.0 mg, 4.0 mg

, Kit, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral

Atrophy of vulva

, 0.25 mg, 0.5 mg, 3.0 mg, 1.0 mg, 4.0 mg

, Kit, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral

Folate supplementation therapy

, 0.25 mg, 0.5 mg, 3.0 mg, 1.0 mg, 4.0 mg

, Kit, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral

Hot flashes

, 0.25 mg, 0.5 mg, 3.0 mg, 1.0 mg, 4.0 mg

, Kit, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral

Warnings

Nikki Contraindications

Condition

Risk Level

Notes

Chronic Kidney Disease

Do Not Combine

Venous Thrombosis

Do Not Combine

Neoplasms, Hormone-Dependent

Do Not Combine

Migraine with Aura

Do Not Combine

Porphyrias

Do Not Combine

Breast

Do Not Combine

suspected pregnancy

Do Not Combine

Breast Milk Production

Do Not Combine

Metrorrhagia

Do Not Combine

Hypersensitivity

Do Not Combine

Liver Failure, Acute

Do Not Combine

Acute Kidney Injury

Do Not Combine

Deep Vein Thrombosis (DVT)

Do Not Combine

Vision Loss

Do Not Combine

Endometrial Hyperplasia

Do Not Combine

Tobacco Use

Do Not Combine

Liver Function Tests

Do Not Combine

Thrombophilia

Do Not Combine

Thromboembolism

Do Not Combine

high risk of arterial thrombotic disease

Do Not Combine

estrogen-dependent neoplasia

Do Not Combine

Liver Neoplasms

Do Not Combine

Adrenal Insufficiency

Do Not Combine

Thrombosis

Do Not Combine

Breast

Do Not Combine

estrogen-dependent neoplasia

Do Not Combine

There are 20 known major drug interactions with Nikki.

Common Nikki Drug Interactions

Drug Name

Risk Level

Description

Tranexamic acid

Major

Drospirenone may increase the thrombogenic activities of Tranexamic acid.

Acetohexamide

Minor

The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Drospirenone.

Agmatine

Minor

The risk or severity of hyperkalemia can be increased when Drospirenone is combined with Agmatine.

Aliskiren

Minor

The risk or severity of hyperkalemia can be increased when Drospirenone is combined with Aliskiren.

Anisodamine

Minor

The risk or severity of hyperkalemia can be increased when Drospirenone is combined with Anisodamine.

Nikki Toxicity & Overdose Risk

The lowest toxic dose of drospirenone in rats has been found to be greater than 2000mg/kg. Those who overdose on drospirenone may experience nausea or bleeding, and may also have changes in their levels of sodium and potassium that should be monitored. Acidosis and high potassium levels may also occur as a result of an overdose.

image of a doctor in a lab doing drug, clinical research

Nikki Novel Uses: Which Conditions Have a Clinical Trial Featuring Nikki?

At present, 104 active studies are being conducted to analyze the utility of Nikki in treating Acne Vulgaris, Post-Menarcheal states and N-Cadherin-related disorders.

Condition

Clinical Trials

Trial Phases

N-Cadherins

0 Actively Recruiting

moderate to severe symptoms

0 Actively Recruiting

Folate supplementation therapy

0 Actively Recruiting

Acne Vulgaris

0 Actively Recruiting

Atrophy of vulva

1 Actively Recruiting

Not Applicable

Hormonal Contraception

0 Actively Recruiting

Hot flashes

30 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Early Phase 1, Phase 3, Phase 1

Post-Menarche

0 Actively Recruiting

Adherence to Oral Contraceptive Therapy

0 Actively Recruiting

Birth Control

14 Actively Recruiting

Not Applicable, Phase 3, Phase 4, Phase 2

Atrophic

4 Actively Recruiting

Phase 3, Phase 4, Not Applicable

Vasomotor System

0 Actively Recruiting

Nikki Reviews: What are patients saying about Nikki?

5

Patient Review

1/14/2019

Nikki for Birth Control

4.3

Patient Review

6/18/2022

Nikki for Premenstrual Disorder with a State of Unhappiness

Nikki has been a total game-changer for me. I had awful PMDD and my periods were so heavy, it would completely drain me. Now, I only have the occasional breakthrough spotting and my mood has dramatically improved. Instead of 10 days of PMS, I now only have a few days. Plus, my periods are much lighter now. Overall, I'm really satisfied with this medication.

3.7

Patient Review

3/24/2019

Nikki for Birth Control

I took this medication for three weeks and started experiencing a whole host of negative side effects, including nausea, loss of appetite, constipation, and then skin sensitivity. My complexion became really inflamed and I was constantly itch. I had to stop taking the medication after that.

2.3

Patient Review

2/11/2020

Nikki for Acne

I had to switch from Gianvi to Nikki at the pharmacy, and it was honestly a terrible experience. Not only did I get really bad acne, but I also experienced severe pigmentation that turned my palms dark brown. This pill is a nightmare and I would not recommend it to anyone.

2.3

Patient Review

3/7/2019

Nikki for Birth Control

I've had no issues with Yaz, Gianvi, and Loryna. However, Nikki (from a different prescription service) gave me more break outs, greasy hair (which I've never had my entire life), and just an overall difference in mood/menstruation during my time of the month.

2.3

Patient Review

10/4/2022

Nikki for Acne

I gained weight while on this medication, which was especially noticeable in my arms and hips. It did clear up my cystic acne, but I still had bad breakouts. I eat healthy and exercise regularly, so I know it wasn't due to changes in my lifestyle. However, it did help with period cramps and flow.

2.3

Patient Review

10/4/2022

Nikki for Acne

I had some serious side effects while taking this birth control, including anxiety and blurred vision. The acne was also really bad. I only took it for six weeks before giving up on it entirely.

2

Patient Review

10/1/2021

Nikki for Acne

My acne got noticeably worse while taking this medication. I also experienced more depression and anxiety. Spotting three or more times a month. Tried for three months, but it didn't work out for me.

2

Patient Review

6/20/2022

Nikki for Birth Control

I switched to this birth control pill from another brand, and I immediately began experiencing more side effects like sporadic bleeding/spotting and yeast infections. Three months was enough for me; I switched off of this last month and am still experiencing mild residual effects. Do not recommend.

1.7

Patient Review

4/29/2022

Nikki for Birth Control

I have never been so disappointed in a treatment before. I was hoping this would help with my depression, anxiety, and mood swings but it only made things worse. If you're considering this birth control, don't bother.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about nikki

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who is blood and Nikki?

"Vlad and Niki are two American brothers who run a YouTube channel. Their parents are from Moscow, Russia, and they have a total of 21 channels in 18 different languages."

Answered by AI

Is Nikki Bella a twin?

"The Bella Twins were a professional wrestling tag team who performed on WWE and consisted of identical twin sisters Brie Bella and Nikki Bella (real names Brianna and Nicole). Each of the Bella Sisters is a former WWE Divas Champion. Brie is the first twin in WWE history to win that title."

Answered by AI

Clinical Trials for Nikki

Image of St. Joseph's Healthcare Hamilton in Hamilton, Canada.

Internet-Delivered Cognitive Behavioural Therapy for Hot Flashes

40 - 60
Female
Hamilton, Canada

Given the impact that hot flashes and night sweats can have on daily life during the menopausal transition, our team has developed a therapist-guided online cognitive behavioural therapy (CBT)- based program to help individuals manage these symptoms. An online program may help address systemic barriers to in-person care, such as cost, time, travel, and caregiving needs. The broad aim of this pilot clinical trial is to examine the experience of a four-week therapist-guided online CBT-based program for menopause-related hot flashes and night sweats. The primary objective of this study is to evaluate the acceptability and feasibility of the four-week online program, including how participants experience the program and how well they are able to complete it at home. The secondary objective is to explore whether the program may help with hot flashes and night sweats, and related concerns such as sleep, mood, anxiety, and quality of life. Exploratory analyses will examine whether changes in these outcomes are maintained three months after completing the program. Researchers will compare participants who receive the program immediately with participants who wait four weeks before receiving it. Participants will: * Complete online questionnaires about their symptoms and well-being. * Complete four weekly online lessons and activities. * Meet briefly with a guide each week for guidance and support. * Complete follow-up questionnaires after the program and three months later.

Waitlist Available
Has No Placebo

St. Joseph's Healthcare Hamilton

Sheryl M Green, PhD, CPsych

Image of MusB Research LLC in New Port Richey, United States.

Ashoka Bark and Shatavari for Menopause

40 - 65
Female
New Port Richey, FL

This 12-week randomized, placebo-controlled clinical trial will evaluate the efficacy and safety of a daily oral supplement containing Ashoka Bark and Shatavari in women experiencing menopausal symptoms. Up to 50 participants will be randomized to receive either the active supplement or placebo, with 40 participants expected to complete the study. Participants will attend visits at Weeks 0, 6, and 12, where hormone levels (FSH and estradiol), menopausal symptoms, quality of life, anxiety, cognitive function, and sleep will be assessed using validated measures. The study will also explore changes in the vaginal microbiome and monitor safety and adherence throughout the trial. The study will be conducted at MusB Research in New Port Richey, Florida.

Recruiting
New This Month

MusB Research LLC

Vidya USA Corporation

Image of Alberta Diabetes Institute in Edmonton, Canada.

Resistance Exercise for Type 1 Diabetes

18+
Female
Edmonton, Canada

Improvements in diabetes care and technology have led to people with type 1 diabetes living longer. There are now more seniors than ever living with this complex health condition. With aging, type 1 diabetes affects both bone (more brittle), and muscle (loss of size and strength). This loss happens faster and to a greater extent in females than in males, and greatly increases the risk of frailty and falls. It may also occur more quickly in individuals who have higher blood glucose (sugar) levels. Frailty is an important factor to address. In older females, even mild frailty decreases the ability to perform day-to-day tasks, and increases the risk of fractures, falls, hospitalization, and even death. Performing regular exercise helps to maintain the strength and quality of both muscles and bones with aging. The best type of exercise to help maintain the ability to perform activities of daily living (known as functional mobility) for this population is currently unknown. Resistance exercise (weightlifting) helps to prevent decreases in mobility in seniors without diabetes. However, in the context of type 1 diabetes, high blood sugar levels could negatively impact these potential strength benefits and low blood glucose could lead to falls. As such, any exercise program that causes swings in glucose levels may hinder rather than help. The goal of this study is to evaluate the effect of weightlifting over a 6-month timeframe on functional mobility in postmenopausal females with type 1 diabetes, compared to a group that does not train. the investigators will also assess its effects on blood sugar variability and the risk of hypoglycemia. Like different medications, not all exercise is equal. Creating more knowledge about the benefits of specific types of exercise in this population will allow us to be more precise in our exercise recommendations for living longer and more independently with type 1 diabetes.

Waitlist Available
Has No Placebo

Alberta Diabetes Institute (+2 Sites)

Jane E Yardley, PhD

Have you considered Nikki clinical trials?

We made a collection of clinical trials featuring Nikki, we think they might fit your search criteria.
Go to Trials
Image of Novum Pharmaceutical Research Services in Las Vegas, United States.

Estradiol/Levonorgestrel Patch for Menopause

40 - 75
Female
Las Vegas, NV

The two products used in this study are transdermal patches that contain selegiline. The test drug is the Estradiol/Levonorgestrel Transdermal Delivery System (TDS). The comparator drug is the Climara Pro® TDS. The purpose of this research study is to compare how the skin tolerates the test TDS and the comparator TDS. The study will evaluate and compare skin irritation and possible allergic-type skin reactions (sensitization) caused by the two products. The comparison will be based on how the skin responds to repeated applications of each TDS. This includes the assessment of skin irritation during the Induction Period and the evaluation of possible allergic or sensitization reactions after the Challenge Period. In addition, the adhesion of each patch (how well the patch sticks to the skin over time) will be regularly checked, as this is important for both product performance and skin safety.

Phase 1
Recruiting

Novum Pharmaceutical Research Services

Corium Innovations, Inc.

Have you considered Nikki clinical trials?

We made a collection of clinical trials featuring Nikki, we think they might fit your search criteria.
Go to Trials
Image of The Ohio State University in Columbus, United States.

Mindfulness-Based Group Visits for Menopause

40 - 60
Female
Columbus, OH

While perimenopause and menopause are natural biological transitions, women may experience a wide range of physical, emotional, and cognitive symptoms. Although pharmacological options for symptom relief are available, these options may not be acceptable or suitable for all women. Integrative approaches for symptom relief, offered through group medical visits, may complement traditional therapies by increasing access to providers, allowing more time for focused education, and fostering supportive discussions with other women experiencing similar symptoms of perimenopause or menopause. The purpose of this study is to assess the effectiveness of eight monthly group medical visits that incorporate individual physical assessments, focused education on the foundational elements of Lifestyle Medicine relative to health and well-being, mindfulness practices, and community-building discussions with women experiencing perimenopause or menopause. Individual outcomes, obtained before the group medical visits begin, at each monthly group medical visit, and four months after the group medical visits are completed, will include measures of participants' perimenopause or menopause symptoms, stress, inflammation, microbiome (good bacteria in the body), height/weight, body mass index (BMI), systolic and diastolic blood pressure, and self-reported perceptions of physical, mental, and social health. Each 120-minute monthly group medical visit, led by a specially trained nurse practitioner and a mindfulness instructor, will include a brief physical assessment, educational discussions related to menopause and lifestyle medicine, experiential mindfulness practices, and the development of individual health and well-being goals.

Waitlist Available
Has No Placebo

The Ohio State University

Image of Banner University Medical Center Phoenix in Phoenix, United States.

DHEA vs Estradiol for Menopause

40 - 90
Female
Phoenix, AZ

This study is being done to compare two vaginal treatments, vaginal estrogen and vaginal DHEA, that are used to treat vaginal and urinary symptoms related to menopause. These symptoms may include vaginal dryness, discomfort, painful intercourse, or urinary problems and can affect quality of life and sexual health. Women who choose to participate will be randomly assigned to use one of the two treatments for a set period of time. Participants will complete questionnaires about their symptoms and sexual health and have simple vaginal testing at the beginning and end of the study. The goal of this research is to better understand how these treatments affect vaginal health and sexual function so healthcare providers can make informed treatment decisions and improve care for postmenopausal women.

Recruiting
Has No Placebo

Banner University Medical Center Phoenix

Molloy Shaida

Image of Albert Einstein College of Medicine in The Bronx, United States.

Vaginal Estradiol vs Moisturizer for Menopause in Women with HIV

40 - 70
Female
The Bronx, NY

This is a research study about the effects of vaginal estradiol compared to moisturizer on vaginal symptoms of menopause and the microbiome in women with HIV. This research study aims to understand how vaginal products affect the aging of the female genital tract in women living with HIV who are menopausal or perimenopausal and have vaginal or urinary symptoms. There is a comparison group of women who are living without HIV. Participants with HIV and vaginal or urinary menopausal symptoms (e.g., dryness, irritation, soreness, itching, pain with sex, dysuria, urgency, or frequent urinary tract infections) will be asked to apply vaginal estradiol or a vaginal moisturizer (Replens). Participants who have vaginal or urinary menopausal symptoms and do not have HIV will receive vaginal estradiol.

Phase 4
Waitlist Available

Albert Einstein College of Medicine

Kerry J Murphy, MD

Have you considered Nikki clinical trials?

We made a collection of clinical trials featuring Nikki, we think they might fit your search criteria.
Go to Trials